Subject: Extension of Timeframe: Invitation to participate in Rapid Communication on mpox
From: "EVD.Outbreak" <[email-masked]>
To: "mateusz.markowicz" <[email-masked]>, "stephan.aberle" <[email-masked]>, "El-Khatib Ziad" <[email-masked]>, "irene.kaszoni-rueckerl" <[email-masked]>, "tinne.lernout" <[email-masked]>, <[email-masked]>, "dominique.vanbeckhoven" <[email-masked]>, "jessika.deblonde" <[email-masked]>, "elica.panayotova" <[email-masked]>, "iva_trrifonova" <[email-masked]>, "mikov" <[email-masked]>, "mtyufekchieva" <[email-masked]>, "nvladimirova"
Cc: "NC_CCB_Austria" <[email-masked]>, "sigrid.kiermayr" <[email-masked]>, "koen.blot" <[email-masked]>, <[email-masked]>, <[email-masked]>, "Iva Christova" <[email-masked]>, "kcapak" <[email-masked]>, "bernard.kaic" <[email-masked]>, "Elisavet Constantinou" <[email-masked]>, <[email-masked]>,Hana Orlíková <[email-masked]>,Kamilla Grønborg Laut <[email-masked]>, "Stine Ulendorf Jacobsen" <[email-masked]>, "TA Info" <[email-masked]>, "Otto Helve" <[email-masked]>, "Savolainen-Kopra Carita" <carita.savolainen-kop
Date: Wed, 14 Feb 2024 18:34:59 +0200

Tähelepanu! Tegemist on väljastpoolt asutust saabunud kirjaga. Tundmatu 
saatja korral palume linke ja faile mitte avada.

ECDC NORMAL

Dear Colleagues,

Following up on our previous email regarding the preparation of a Rapid 
Communication addressing the recent upsurge in cases in the European Region, 
we are extending the timeframe for submitting details of interested 
participants until EOD February 16, 2024. If your country is interested in 
participating, kindly provide the required information outlined in the 
previous communication by the updated deadline. Thank you to all who have 
responded so far.

As previously communicated, we are inviting countries that have reported 
mpox cases through TESSy since August 2022 to participate in this 
peer-reviewed Rapid Communication. Please note that we will limit the number 
of co-authors to one to two persons per country, with the possibility of 
including additional colleagues in the acknowledgements section.

If your country is interested to participate, please let us know who the 
contributors will be, their full affiliation and a declaration that the 
co-authors have no conflict of interest regarding the publication of this 
manuscript using the table below.

First name

Last name

Full affiliation

Confirmation of no conflict of interest

Email

Please send your reply directly to  <mailto:[email-masked]> 
[email-masked] and [email-masked] 
<mailto:[email-masked]> .

Thank you for your interest and continued collaboration.

Best regards,

The WHO EURO and ECDC mpox teams

European Centre for Disease Prevention and Control (ECDC)Gustav III:s boulevard 40, 169 73 Solna, Sweden

Phone +46 (0)8 58 60 10 00

 <https://www.ecdc.europa.eu/> www.ecdc.europa.eu

Follow ECDC on:

 <http://www.facebook.com/ECDC.EU>

 <http://twitter.com/ecdc_eu>

 <http://www.linkedin.com/company/ecdc>

 <http://www.youtube.com/user/ECDCchannel>

From: EVD.Outbreak
Sent: Monday, February 5, 2024 7:17 PM
To: [email-masked]; [email-masked]; 
[email-masked]; [email-masked]; 
[email-masked]; [email-masked]; 
[email-masked]; [email-masked]; 
[email-masked]; [email-masked]; [email-masked]; 
[email-masked]; [email-masked]; 
[email-masked]; [email-masked]; 
[email-masked]; [email-masked]; 
[email-masked]; [email-masked]; 
[email-masked]; [email-masked]; [email-masked]; 
[email-masked]; [email-masked]; 
[email-masked]; [email-masked]; [email-masked]; 
[email-masked]; [email-masked]; [email-masked]; pvb <[email-masked]>; 
[email-masked]; [email-masked]; [email-masked]; 
[email-masked]; Jevgenia Epštein 
<[email-masked]>; [email-masked]; pamela.osterlund 
<[email-masked]>; [email-masked]; [email-masked]; 
[email-masked]; 
[email-masked]; 
[email-masked]; [email-masked]; 
frankc <[email-masked]>; [email-masked]; [email-masked]; 
[email-masked]; [email-masked]; 
[email-masked]; [email-masked]; [email-masked]; 
[email-masked]; [email-masked]; 
[email-masked]; [email-masked]; 
[email-masked]; [email-masked]; 
[email-masked]; [email-masked]; [email-masked]; 
[email-masked]; [email-masked]; [email-masked]; 
[email-masked]; [email-masked]; [email-masked]; 
[email-masked]; [email-masked]; [email-masked]; 
[email-masked]; [email-masked]; 
[email-masked]; [email-masked]; 
[email-masked]; [email-masked]; [email-masked]; 
[email-masked]; [email-masked]; [email-masked]; 
[email-masked]; [email-masked]; 
[email-masked]; [email-masked]; [email-masked]; 
[email-masked]; Sadkowska-Todys Malgorzata 
<[email-masked]>; [email-masked]; 
[email-masked]; [email-masked]; 
[email-masked]; [email-masked]; 
[email-masked]; [email-masked]; [email-masked]; 
jana.kerlik <[email-masked]>; [email-masked]; 
[email-masked]; eva.chmelanova <[email-masked]>; 
[email-masked]; maja.socan <[email-masked]>; [email-masked]; 
[email-masked]; [email-masked]; [email-masked]; 
[email-masked]; [email-masked]; [email-masked]; 
[email-masked]; 
[email-masked]; 
[email-masked]; 
[email-masked]; 
[email-masked]
Cc: [email-masked]; [email-masked]; 
[email-masked]; [email-masked]; [email-masked]; 
[email-masked]; [email-masked]; bernard.kaic 
<[email-masked]>; [email-masked]; [email-masked]; 
[email-masked]; [email-masked]; [email-masked]; [email-masked]; 
[email-masked]; [email-masked]; 
[email-masked]; Anne-Catherine VISO 
<[email-masked]>; [email-masked]; [email-masked]; 
[email-masked]; [email-masked]; [email-masked]; 
[email-masked]; [email-masked]; phc.office 
<[email-masked]>; [email-masked]; 
[email-masked]; Greg Martin <[email-masked]>; Kate 
Loughnane <[email-masked]>; [email-masked]; 
[email-masked]; Lisa.Domegan <[email-masked]>; kirsty.mackenzie 
<[email-masked]>; Francesco Maraglino <[email-masked]>; 
[email-masked]; [email-masked]; 
[email-masked]; [email-masked]; [email-masked]; 
Macdonald, Emily Ann <[email-masked]>; [email-masked]; 
[email-masked]; [email-masked]; 
[email-masked]; [email-masked]; [email-masked]; 
Adriana Pistol <[email-masked]>; ecdc <[email-masked]>; 
[email-masked]; [email-masked]; Marta.vitek <[email-masked]>; 
[email-masked]; [email-masked]; 
[email-masked]; 
[email-masked]; 
[email-masked]; 
[email-masked]; 
[email-masked]; episurveillance 
<[email-masked]>; EVD.Outbreak <[email-masked]>; ECDC 
Info <[email-masked]>
Subject: For action: Invitation to participate in Rapid Communication on 
mpox

Dear Colleagues,

WHO Regional Office for Europe and ECDC would firstly like to thank you for 
submitting national case-based mpox data to TESSy on a monthly basis. This 
data has been critical to support global situational analysis and to guide 
public health actions at national, regional and global levels.

In light of the recent upsurge in cases in the European Region, we are 
currently analyzing TESSy data with the aim of preparing a Rapid 
Communication (target journal: Eurosurveillance). The aim of this manuscript 
is to provide an overview of the recent epidemiological situation covering 
the period from August 2022 to February, and will build on the previous 
<https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2022.27.36.2200620> 
manuscript, the quarterly regional EURO/ECDC surveillance report 
<https://monkeypoxreport.ecdc.europa.eu/>  and other global WHO outputs 
<https://www.who.int/emergencies/situation-reports> .

We would hereby like to invite countries who reported mpox cases through 
TESSy since August 2022 to participate in the preparation of this 
peer-reviewed Rapid Communication. We will limit the number of co-authors to 
a one to two persons per country, but there will be the possibility to 
include further colleagues in the acknowledgements.

If your country is interested to participate, please let us know who the 
contributors will be, their full affiliation and a declaration that the 
co-authors have no conflict of interest regarding the publication of this 
manuscript by sending us the below table filled out at your earliest 
convenience and latest by Wednesday 14 February 2024 EOB. Please send your 
reply directly to [email-masked] <mailto:[email-masked]> 
and  <mailto:[email-masked]> [email-masked].

First name

Last name

Full affiliation

Confirmation of no conflict of interest

The contributors will be expected to be available for data checks, to 
critically revise the results of the analysis and to review and comment on 
the various versions of the manuscript with short deadlines in the next 3 to 
4 weeks. All authors need to meet the 
<http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html> 
ICMJE authorship criteria.

In advance of the next reporting deadline on 8 February 2024, countries are 
requested to ensure adequate completeness of the mandatory TESSy variables, 
including key demographic, clinical and exposure variables. In addition to 
the data submitted through TESSy, we also invite any information you may 
have on significant mpox-related events, such as localized increases (an 
unexpected rise in cases in a specific city, province or region), clusters 
of cases linked to a gathering event (especially gatherings with 
international participation), nosocomial outbreaks, and other events 
considered significant by Member States.

In summary:

1.	Please ensure completeness for key variables in next TESSy report on 
Thursday 8 February 2024
2.	If you are interested in participating in this manuscript, please 
complete the table above with two co-authors from your country (deadline 
Wednesday 14 February 2024 EOB) and share with WHO and ECDC email addresses 
above.
3.	Co-authors to be available for data checks, results analysis and 
manuscript review over next 3-4 weeks.

Please do not hesitate to contact us if you have any questions at 
[email-masked] <mailto:[email-masked]>  and 
<mailto:[email-masked]> [email-masked].

Best regards,

The WHO EURO and ECDC teams

European Centre for Disease Prevention and Control (ECDC)Gustav III:s boulevard 40, 169 73 Solna, Sweden

Phone +46 (0)8 58 60 10 00

 <https://www.ecdc.europa.eu/> www.ecdc.europa.eu

Follow ECDC on:

 <http://www.facebook.com/ECDC.EU>

 <http://twitter.com/ecdc_eu>

 <http://www.linkedin.com/company/ecdc>

 <http://www.youtube.com/user/ECDCchannel>

Confidentiality Notice
If you are not the intended recipient of this message, you are hereby kindly 
requested, to, consecutively, refrain from disclosing its content to any 
third party, delete it and inform its sender of the erroneous transmittal.